AgomAb: antibodies driving tissue regeneration and recovery
Emerging Company Profile: argenx spinout AgomAb raises $74M series B to complete clinical POC for lead mAb and grow pipeline
AgomAb parlayed what began as a cancer drug discovery partnership into an antibody program that could drive tissue regeneration and organ recovery.
On Wednesday, the Belgian biotech raised $74 million in a series B round led by Redmile Group and joined by Cormorant Asset Management, setting the stage for a potential near-term IPO. All of the company’s existing investors also participated. ...